Get started
Author

Conn M. Harrington

Observed names: C. Harrington, Conn Harrington, Conn M Harrington
Observed institutions: GlaxoSmithKline (United Kingdom), Universidad de Guadalajara, ViiV Healthcare (United Kingdom), Broward Health Medical Center, GlaxoSmithKline (United States), Durham Public Schools, University of Nebraska Medical Center
ORCID: 0009-0001-7319-0330
Observed ORCID: 0009-0001-7319-0330
OpenAlex ID: A5008537066
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
2020 · Susan Swindells, Jaime-Federico Andrade-Villanueva, et al. · New England Journal of Medicine · 638
PDF
Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
2011 · C. Harrington, S. Sawchak, et al. · Current Alzheimer Research · 200
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
2020 · Giuliano Rizzardini, Edgar T. Overton, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 172
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
2023 · Edgar T Overton, Gary Richmond, et al. · Clinical Infectious Diseases · 157
PDF
A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease
2014 · Richard Grove, Conn Harrington, et al. · Current Alzheimer Research · 113
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
2021 · Susan Swindells, Thomas Lutz, et al. · AIDS · 99
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
2024 · Aditya H Gaur, Edmund V Capparelli, et al. · The Lancet HIV · 37
PDF
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
2024 · Elizabeth D Lowenthal, Jennifer Chapman, et al. · The Lancet HIV · 31
PDF
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
2026 · Aditya H Gaur, Kristin Baltrusaitis, et al. · The Lancet HIV · 8
PDF
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study
2025 · Susan L Ford, Franco Felizarta, et al. · Clinical Infectious Diseases · 8
P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified Subjects With Mild‐to‐moderate Alzheimer's Disease
2009 · Conn Harrington, Sharon Sawchak, et al. · Alzheimer s & Dementia · 8
PDF
1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
2020 · Christine L Talarico, Sterling Wu, et al. · Open Forum Infectious Diseases · 5
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
2019 · Paula Teichner, Amy Cutrell, et al. · Open Forum Infectious Diseases · 5
Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
2026 · Elizabeth D Lowenthal, Jennifer Chapman, et al. · The Lancet HIV · 4
PDF
Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1
2025 · Ronald D’Amico, Kelong Han, et al. · AIDS · 4
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
2025 · Rosie Mngqibisa, Yashna Singh, et al. · Southern African Journal of HIV Medicine · 3
PDF
P-545. Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers
2025 · Cassidy Gutner, Conn M Harrington, et al. · Open Forum Infectious Diseases · 2
PDF
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials
2022 · Maggie Czarnogorski, Paul Benn, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2
LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
2020 · Ronald D'Amico, Paul Benn, et al. · Open Forum Infectious Diseases · 2
PDF
Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial
2026 · Carolyn Bolton Moore, Kristin Baltrusaitis, et al. · The Lancet Child & Adolescent Health
Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study
2026 · Cassidy A. Gutner, Conn Harrington, et al. · Journal of the International Association of Providers of AIDS Care (JIAPAC)
P4‐418: A randomized, double‐blind, placebo‐controlled 16 week study of the H3 receptor antagonist GSK239512 in subjects with mild‐to‐moderate Alzheimer's disease (AD)
2011 · Richard Grove, Joseph Horrigan, et al. · Alzheimer s & Dementia
Works count: 22
Citation count: 1,498
H-index: 8
I10-index: 8
Year
Topic
Type